Corgenix suffers arthritis test setback
This article was originally published in Clinica
Corgenix Medical has decided to withdraw its 510(k) application to market in the US a diagnostic test for rheumatoid arthritis. The move came after it was established from discussions with the FDA that further clinical information would be required to obtain clearance.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.